Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Preimplantation Factor essential for pregnancy to succeed: Study

Researchers at Yale School of Medicine and their colleagues at the Society for the Investigation of Early Pregnancy have helped clarify the function of a unique protein called Preimplantation Factor, which is produced by healthy embryos to direct embryo attachment and help the mother adapt to pregnancy.

29 May 2010

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

If you're headed to a freshwater stream this summer and a friend dares you to eat a raw crayfish - don't do it. You could end up in the hospital with a severe parasitic infection.

27 May 2010

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

Alvine Pharmaceuticals, Inc., a privately held clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/inflammatory diseases, today announced that Abbott Biotech Ventures Inc., has joined Alvine's current investors: Interwest Partners, Panorama Capital, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures in the company's Series A Extension financing. The terms of the investment were not disclosed.

27 May 2010

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

26 May 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

A novel study by researchers at the University of California, San Francisco found that nearly one-third of Rheumatoid Arthritis (RA) patients differed from their physicians in assessment of their disease severity. The disagreement between patient and doctor evaluation of RA activity was most prevalent in patients with depressive symptoms, and those who had poor overall function.

26 May 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).

25 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche and Biogen Idec today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA).

19 May 2010

Is gluten the latest villain in the battle for better health?

If you've been food shopping or out to eat lately, you've probably noticed that "gluten-free" foods now claim their own grocery store shelves and dozens of national restaurant chain menus highlight "gluten-free" entrees.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

Karolinska Institutet researchers discover new control mechanism in immune system

Researchers at the Swedish medical university Karolinska Institutet have discovered a new control mechanism in our immune system. The discovery is of potential significance to the treatment of serious diseases such as MS (multiple sclerosis), rheumatoid arthritis, and SLE (Systemic lupus erythematosus).

4 May 2010

Autoimmune Disease News and Research

Further Reading

Preimplantation Factor essential for pregnancy to succeed: Study

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

New journal to focus on autoimmune disease research and development

Study finds disagreement between RA patients and doctors on assessment of disease severity

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Is gluten the latest villain in the battle for better health?

Athersys presents data supporting MultiStem programs

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Karolinska Institutet researchers discover new control mechanism in immune system

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News